Pharmacogenetics of Oral Anticoagulants
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 47 (9), 565-594
- https://doi.org/10.2165/00003088-200847090-00002
Abstract
No abstract availableKeywords
This publication has 103 references indexed in Scilit:
- Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patientsThrombosis Research, 2007
- Comparative Pharmacokinetics of Vitamin K AntagonistsClinical Pharmacokinetics, 2005
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- Pharmacogenetics of Warfarin Elimination and its Clinical ImplicationsClinical Pharmacokinetics, 2001
- Validation of Methods for CYP2C9 Genotyping: Frequencies of Mutant Alleles in a Swedish PopulationBiochemical and Biophysical Research Communications, 1999
- Clinically Important Drug Interactions with AnticoagulantsClinical Pharmacokinetics, 1996
- Antithrombotic therapy in deep vein thrombosis and pulmonary embolismAmerican Heart Journal, 1992
- Comparison of the bioavailabilities and anticoagulant activities of two warfarin formulationsBritish Journal of Haematology, 1982
- Clinical Pharmacokinetics of Oral AnticoagulantsClinical Pharmacokinetics, 1979
- Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in manJournal of Pharmacy and Pharmacology, 1973